查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球脊髓刺激市场 - 2023-2030
市场调查报告书
商品编码
1348006

全球脊髓刺激市场 - 2023-2030

Global Spinal Cord Stimulation Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 183 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

脊髓刺激 (SCS) 是一种相对较新的技术，当原因无法完全治疗或损伤无法修復时，可以帮助控制慢性疼痛。脊髓刺激疗法可以缓解症状并改善日常功能。

脊髓刺激使用温和的电流来刺激脊髓中的某些神经纤维。脊髓刺激有助于有针对性地缓解疼痛。它可以帮助治疗躯干和/或四肢的慢性顽固性疼痛，包括单侧或双侧疼痛。脊髓刺激可以改善整体生活品质和睡眠，并减少对止痛药的需求。

动力学

先进设备的推出数量增加预计将加速市场成长

先进的脊髓刺激器有助于为患有慢性疼痛的患者提供有效的治疗，从而增加对设备的需求并推动市场成长。例如，2022 年1 月24 日，全球医疗保健技术领导者美敦力公司(Medtronic Plc) 推出了两种高度先进的脊髓刺激设备：Intellis 可充电神经刺激器和Vanta 免充电神经刺激器，用于治疗与糖尿病週边神经病变(DPN) 相关的慢性疼痛。

此外，2022 年 10 月 12 日，Nevro Corp.（一家为治疗慢性疼痛提供全面、改变生活的解决方案的全球医疗器材公司）开发了 Senza HFX iQ 脊髓刺激 (SCS) 系统。 Senza HFX iQ 是第一个也是唯一一个基于人工智慧、向病患学习的 SCS 系统。

脊髓损伤数量的增加以及慢性病患者越来越多地采用脊髓刺激器作为药物的替代品，预计将推动市场成长。

治疗过程的高成本预计将阻碍市场成长

治疗的高成本可能会导致患者从脊髓刺激转向其他低成本药物和止痛药，进而影响市场成长。根据华盛顿州劳工和工业部资助的一项研究，植入脊髓刺激系统的平均总医疗费用为每位患者 19,246 美元至 47,190 美元。

其他因素，例如与脊髓刺激和脊髓液渗漏相关的併发症，可能会阻碍市场的成长。因此，它影响了市场的成长。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按设备类型分類的片段
  • 按指示显示的片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 先进设备的发布数量增加
    • 限制
      • 治疗费用高
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 俄乌战争影响分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按装置类型

  • 可充电植入式脉衝产生器
  • 不可充电
  • 传统植入式脉衝产生器
  • 射频刺激器

第 8 章：依指示

  • 失败背部症候群（FBS）
  • 退化性椎间盘疾病
  • 复杂区域疼痛综合症（CRPS）
  • 手术后疼痛
  • 蜘蛛网膜炎
  • 其他的

第 9 章：最终用户

  • 医院
  • 专科诊所
  • 骨科中心
  • 其他的

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Medtronic Plc
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Abbott Laboratories
  • Synapse Biomedical (SBI)
  • Boston Scientific Corporation
  • Curonix LLC,
  • Cirtec Medical
  • Nevro Corporation
  • Gimer Medical.
  • Beijing Pinchi Medical Equipment Co., Ltd.
  • Saluda Medical Pty Ltd.

第 13 章：附录

简介目录
Product Code: MD2176

Overview

Spinal cord stimulation (SCS) is a relatively new technology that can help manage chronic pain when the cause cannot be treated completely or the injury cannot be repaired. Spinal cord stimulation therapy offers relief and improved daily functioning.

Spinal cord stimulation uses a mild electrical current to stimulate certain nerve fibers in the spinal cord. Spinal cord stimulation helps in targeted pain relief. It is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs-including unilateral or bilateral pain. Spinal cord stimulation can improve overall quality of life and sleep and reduce the need for pain medicines.

Dynamics

Increased number of launches of advanced devices is expected to accelerate the market growth

Advanced spinal cord stimulators help provide efficient treatment to patients suffering from chronic pain, thus, increasing the demand for the devices and driving the market growth. For instance, on January 24, 2022, Medtronic Plc, a global leader in healthcare technology, introduced two highly advanced spinal cord stimulating devices, Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator for treating chronic pain associated with diabetic peripheral neuropathy (DPN).

Furthermore, on October 12, 2022, Nevro Corp., a global medical device company that delivers comprehensive, life-changing solutions for the treatment of chronic pain, developed the Senza HFX iQ spinal cord stimulation (SCS) system. Senza HFX iQ is the first and only Artificial Intelligence-based SCS system that learns from patients.

The increase in the number of spinal cord injuries and the increase in the adoption of spinal cord stimulators by chronic disease patients as an alternative to medication are the additional factors that are expected to drive the market growth.

High cost of the treatment procedure is expected to hinder market growth

The high cost of the treatment can affect the market growth by allowing the patients to shift from spinal cord stimulation to other low-cost drugs and painkillers. According to a study funded by the Washington State Department of Labor and Industries, the average total medical costs of implanting a spinal cord stimulating system range from $19,246-$47,190 per patient.

Other factors, such as complications associated with spinal cord stimulation and leakage in the spinal fluid, can hamper the market growth. Thus, it affects the market growth.

Segment Analysis

The global spinal cord stimulation market is segmented based on device type, indication, end-user, and region.

Rechargeable implantable pulse generator segment holds a significant position in the market share

The increase in the number of approvals of rechargeable implantable pulse generators is expected to hold a significant position in the market growth. For instance, BIOTRONIK, on April 19, 2023, received U.S. Food and Drug Administration (FDA) approval for Prospera, a spinal cord stimulation (SCS) system. The system features RESONANCE, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support.

Additionally, on December 19, 2022, Abbott received the US Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which it claims is the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Thus, an increase in the number of product approvals is expected to hold the segment in the dominant position.

Geographical Penetration

North America holds the largest market share in the global spinal cord stimulation market

North America holds a dominant market share due to the increase in the number of FDA approvals. Launches and distribution of a large number of products help make the treatment available to a number of individuals.

For instance, on January 19, 2022, Nevro Corp., a global medical device company, received FDA approval for expanded labeling for its Senza Spinal Cord Stimulation (SCS) System for treating Non-Surgical Refractory Back Pain (NSRBP).

Additionally, on May 16, 2023, Abbott received the U.S. Food and Drug Administration (FDA) approval for expanding its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain. Thus, increasing the number of FDA approvals is expected to drive the region's market share.

Competitive Landscape

Medtronic Plc, Abbott Laboratories, Synapse Biomedical (SBI), Boston Scientific Corporation, Curonix LLC, Cirtec Medical, Nevro Corporation, Gimer Medical., Beijing Pinchi Medical Equipment Co., Ltd., and Saluda Medical Pty Ltd. are the leading companies with significant market share.

Key Developments

  • On August 25, 2023, Medtronic plc, a global leader in healthcare technology, received CE Mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator (SCS).

COVID-19 Impact Analysis

COVID-19 has impacted the spinal cord stimulation market moderately. The treatment procedures have been postponed, and the follow-ups after the treatment procedures have been delayed. The development and manufacturing of the devices has been halted. This created a negative impact on the growth of the market.

Market Segmentation

By Device Type

  • Rechargeable implantable pulse generator
  • Conventional implantable pulse generator
  • Non-rechargeable
  • Radiofrequency stimulator

By Indication

  • Failed Back Syndrome (FBS)
  • Degenerative Disk Disease
  • Complex regional pain syndrome (CRPS)
  • Post-surgical pain
  • Arachnoiditis
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Orthopedic centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global spinal cord stimulation market segmentation based on device type, indication, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of spinal cord stimulation market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global spinal cord stimulation market report would provide approximately 61 tables, 59 figures, and 183 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased number of launches of advanced devices
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of the treatment procedures
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. Rechargeable implantable pulse generator *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Non-rechargeable
  • 7.4. Conventional implantable pulse generator
  • 7.5. Radiofrequency stimulator

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Failed Back Syndrome (FBS) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Degenerative Disk Disease
  • 8.4. Complex regional pain syndrome (CRPS)
  • 8.5. Post-surgical pain
  • 8.6. Arachnoiditis
  • 8.7. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Orthopedic Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Medtronic Plc *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Abbott Laboratories
  • 12.3. Synapse Biomedical (SBI)
  • 12.4. Boston Scientific Corporation
  • 12.5. Curonix LLC,
  • 12.6. Cirtec Medical
  • 12.7. Nevro Corporation
  • 12.8. Gimer Medical.
  • 12.9. Beijing Pinchi Medical Equipment Co., Ltd.
  • 12.10. Saluda Medical Pty Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us